The US FDA has approved Mesoblast's Ryoncil (remestemcel-L-rknd) for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients 2 months and older. …
FDA approves Mesoblast's cell therapy to treat steroid-refractory acute graft-versus-host disease
December 19, 2024 Australian Biotech
Latest Video
New Stories
-
Medicines Australia seeks answers on AI in HTA process
September 23, 2026 - - Latest News -
The prevention gap and inside Sally Panton's bet on cellular health
September 23, 2026 - - Latest News -
Pfizer 'deeply disappointed' in response to PBAC refusing to move on price
September 23, 2026 - - Latest News -
Lilly goes direct with a patient platform for its non-PBS medicines
September 23, 2026 - - Latest News -
A 'multistakeholder' reference group to shadow agreement negotiations
September 23, 2026 - -
If there is a productivity gain in the process, then it should be passed on
September 22, 2026 - - Latest News -
Given the official use of AI, a cease and desist would not be unreasonable
September 22, 2026 - - Latest News